Last reviewed 2026-05-13 · How we verify

Taxane plus Intermittent Capecitabine

Taxane plus Intermittent Capecitabine is a Combination chemotherapy (taxane + fluoropyrimidine) Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Metastatic breast cancer, Gastric cancer, Other solid tumors (under investigation in phase 3 trials).

A combination regimen that uses taxane chemotherapy to disrupt microtubule dynamics and kill rapidly dividing cancer cells, paired with intermittent capecitabine to provide additional cytotoxic activity and potentially improve tolerability through dosing intermittency.

A combination regimen that uses taxane chemotherapy to disrupt microtubule dynamics and kill rapidly dividing cancer cells, paired with intermittent capecitabine to provide additional cytotoxic activity and potentially improve tolerability through dosing intermittency. Used for Metastatic breast cancer, Gastric cancer, Other solid tumors (under investigation in phase 3 trials).

At a glance

Mechanism of action

Taxanes (such as paclitaxel or docetaxel) stabilize microtubules and prevent their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Capecitabine is a fluoropyrimidine prodrug that is converted to 5-fluorouracil, inhibiting thymidylate synthase and disrupting DNA synthesis. The intermittent dosing schedule of capecitabine is designed to reduce cumulative toxicity while maintaining efficacy.

Approved indications

• Metastatic breast cancer
• Gastric cancer
• Other solid tumors (under investigation in phase 3 trials)

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Peripheral neuropathy
• Nausea/vomiting
• Diarrhea
• Hand-foot syndrome
• Fatigue

Key clinical trials

• Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer (PHASE3)
• Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (PHASE3)
• 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (PHASE3)
• Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Taxane plus Intermittent Capecitabine CI brief — competitive landscape report
• Taxane plus Intermittent Capecitabine updates RSS · CI watch RSS
• Sun Yat-sen University portfolio CI

Frequently asked questions about Taxane plus Intermittent Capecitabine

Related

• Drug class: All Combination chemotherapy (taxane + fluoropyrimidine) drugs
• Target: All drugs targeting Microtubules (taxane); thymidylate synthase (capecitabine/5-FU)
• Manufacturer: Sun Yat-sen University — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Metastatic breast cancer
• Indication: Drugs for Gastric cancer
• Indication: Drugs for Other solid tumors (under investigation in phase 3 trials)
• Compare: Taxane plus Intermittent Capecitabine vs similar drugs
• Pricing: Taxane plus Intermittent Capecitabine cost, discount & access